Valuation : Neuland Laboratories Limited

Market Cap 291B 3.08B 2.65B 2.49B 2.28B 4.26B 4.27B 29.44B 11.42B 149B 11.55B 11.3B 480B P/E 2027 *
60.8x
P/E 2028 * 46.5x
Enterprise Value 293B 3.1B 2.67B 2.51B 2.3B 4.29B 4.31B 29.7B 11.52B 150B 11.66B 11.4B 484B EV / Sales 2027 *
12x
EV / Sales 2028 * 9.96x
Free-Float
62.26%
Yield 2027 *
0.1%
Yield 2028 * 0.14%
1 day-1.21%
1 week-3.62%
Current month-1.27%
1 month+15.46%
3 months+33.27%
6 months+72.91%
Current year+49.06%
1 week 22,400
Extreme 22400
23,325
1 month 19,252.75
Extreme 19252.75
23,899
Current year 11,500
Extreme 11500
23,899
1 year 11,500
Extreme 11500
23,899
3 years 3,424.45
Extreme 3424.45
23,899
5 years 965.85
Extreme 965.85
23,899
10 years 247.3
Extreme 247.3
23,899
Manager TitleAgeSince
Chief Executive Officer 47 01/04/2026
Director of Finance/CFO - 23/11/2022
Chief Tech/Sci/R&D Officer - 01/03/2023
Director TitleAgeSince
Director/Board Member 50 01/01/2002
Chairman 82 07/01/1984
Director/Board Member 47 01/03/2007
Change 5-day change 1-year change 3-year change Capi.($)
-1.21%-3.62%+57.73%+497.69% 3.11B
-1.40%-2.82%+53.65%+104.49% 1,034B
-1.04%+2.71%+54.01%+71.33% 671B
-1.51%+0.40%+20.43%+75.57% 460B
+0.14%-0.47%+29.49%+38.56% 353B
-1.33%+4.72%+24.69%+45.55% 309B
-1.15%+0.30%-1.49%+12.31% 255B
-1.56%+1.01%+55.94%+71.95% 240B
-0.88%+1.15%-17.09%-54.39% 207B
-0.46%+3.17%+33.28%+99.97% 188B
Average -1.03%+0.90%+31.06%+96.30% 371.99B
Weighted average by Cap. -1.11%+1.04%+36.31%+66.60%

Financials

2027 *2028 *
Net sales 24.43B 259M 223M 210M 191M 358M 359M 2.48B 961M 12.54B 972M 951M 40.39B 29.27B 310M 267M 251M 229M 429M 430M 2.97B 1.15B 15.02B 1.16B 1.14B 48.37B
Net income 4.8B 50.82M 43.73M 41.15M 37.59M 70.31M 70.5M 486M 189M 2.46B 191M 187M 7.93B 6.26B 66.35M 57.1M 53.72M 49.07M 91.8M 92.05M 635M 246M 3.21B 249M 244M 10.35B
Net Debt 2.56B 27.13M 23.34M 21.96M 20.06M 37.53M 37.63M 260M 101M 1.31B 102M 99.64M 4.23B 979M 10.37M 8.93M 8.4M 7.67M 14.35M 14.39M 99.24M 38.51M 502M 38.95M 38.1M 1.62B
Logo Neuland Laboratories Limited
Neuland Laboratories Ltd. is a global provider of active pharmaceutical ingredients (APIs) contract development and manufacturing organization (CDMO) services. It is focused on manufacture and sale of active pharmaceutical ingredients and allied services. It supports biotechnology and pharmaceutical companies in the design, development and manufacturing of complex APIs. It has two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). It develops and manufactures non-exclusive APIs both Prime APIs comprising large volume, mature molecules, and specialty APIs comprising lower volume, complex molecules with less competition. It develops small molecules and peptides for clinical trials and beyond. It provides an end-to-end continuum of customized services from early-stage drug development (Pre-IND) through to commercial manufacturing of complex APIs, including process development, process optimization, analytical testing, and regulatory support.
Employees
2,183
Date Price Change Volume
04/09/26 22,643.30 -1.21% 1,382
03/09/26 ₹22,920.60 -0.15% 677
02/09/26 ₹22,955.85 -0.35% 2,101
01/09/26 ₹23,036.00 +0.44% 1,283
31/08/26 ₹22,934.20 -1.25% 2,327
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
22,643.30INR
Average target price
24,334.75INR
Spread / Average Target
+7.47%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NEULANDLAB Stock